Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul 29:2018:6782736.
doi: 10.1155/2018/6782736. eCollection 2018.

Efficacy of Transdermal Oxybutynin in the Treatment of Overactive Bladder Syndrome: Does It Make Sense Using It in 2017?

Raúl Vozmediano-Chicharro  1 , Blanca Madurga  2 , Pedro Blasco  3
Affiliations

Efficacy of Transdermal Oxybutynin in the Treatment of Overactive Bladder Syndrome: Does It Make Sense Using It in 2017?

Raúl Vozmediano-Chicharro et al. Adv Urol. .

Abstract

Objectives: Evaluation of changes in symptoms among patients with overactive bladder syndrome treated with transdermal oxybutynin and tolerability after 12 months of follow-up.

Methods: This was a multicenter, retrospective, single-cohort, observational study. Changes in symptoms were evaluated primarily with a 3-day voiding diary. Results were compared to baseline. Subgroup analyses were performed in patients previously treated for OAB or not and aged < 65 years versus ≥65 years.

Results: Clinical records of 105 patients were examined; 92.4% were women. At 12 months, 58 patients continued to receive transdermal oxybutynin. Changes in symptoms according to the voiding diary were evaluated in 47 patients. Significant improvements from baseline were observed in urinary frequency (-2.6 voids/24 hours (95% CI: -3.5; -1.8), p < 0.001); daily number of urgent episodes (-4.7 episodes/day (95% CI: -6.1; -3.6), p < 0.001); and urge incontinence (-1.9 episodes/day (95% CI: -2.9; -1.3), p < 0.001). No statistically significant differences were found in subgroup analyses. In total, 38.1% of patients had adverse events, primarily in the application site (27.6%). No severe systemic adverse events occurred. Only 6 patients (5.7%) reported dry mouth.

Conclusions: Improved symptoms and good tolerability observed after 1 year of treatment with transdermal oxybutynin shows that it currently has a place in the treatment of OAB patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study flow chart. Patients evaluated for study objectives according to data collected in clinical records. ∗Frequency, urgency, and urge incontinence. OXY-TDS: transdermal oxybutynin. 3 DVD: 3-day voiding diary.
See this image and copyright information in PMC

References

    1. Abrams P., Cardozo L., Fall M., et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-Committee of the International Continence Society. American Journal of Obstetrics and Gynecology. 2002;187(1):116–126. doi: 10.1067/mob.2002.125704. - DOI - PubMed
    1. Martinez Agullo E., Ruiz Cerda J. L., Gomez Perez L., et al. Prevalence of urinary incontinence and hyperactive bladder in the Spanish population: results of the EPICC study. Actas Urologicas Españolas. 2009;33(2):159–166. doi: 10.4321/s0210-48062009000200011. - DOI - PubMed
    1. Novara G., Galfano A., Secco S., et al. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. European Urology. 2008;54(4):740–764. doi: 10.1016/j.eururo.2008.06.080. - DOI - PubMed
    1. Chapple C. R., Martinez-Garcia R., Selvaggi L., et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the STAR trial. European Urology. 2005;48(3):464–470. doi: 10.1016/j.eururo.2005.05.015. - DOI - PubMed
    1. Davila G. W., Starkman J. S., Dmochowski R. R. Transdermal oxybutynin for overactive bladder. Urologic Clinics of North America. 2006;33(4):455–463. doi: 10.1016/j.ucl.2006.06.005. - DOI - PubMed

LinkOut - more resources